The production of advanced therapies, such as CAR-T therapies, is limited by the inefficiencies in the monitoring of cell cultures Furthermore, current technologies do not allow an optimum quality control, which affects scalability and increases costs.
Prospect Biotech offers a solution based on Raman spectroscopy and its enhanced mode with SERS nanoparticles, which function in a complementary manner. Integrated with Artificial Intelligence, these technologies allow the contactless detection of multiple parameters, optimising production in real time. The combination of both improves sensitivity when detecting biomarkers and identifying patterns, which lowers risks and improves productivity in the bioproduction of advanced therapies.
Tagline: Optic technology to optimise the production and effectiveness of the new advanced therapies.
Financing needs: €437,000 first 2.5-3 years (first round) for: Technological development: advanced prototypes, validation in real settings, sensor enhancement and customisation. Operating expenditure: salaries for researchers and business developers, administrative costs. Legal services and patent protection.
The market includes biotech companies, pharmaceuticals, hospitals and research centres. Prospect Biotech targets those firms developing advanced therapies, such as CAR-T cell therapies, bioproduction of viral vectors, cultured meat, along with research laboratories and universities.
Fill in this form and we will contact you if you want to take part in this initiative – either by contributing technology assets or if you are a talent promoter capable of turning them into business projects.
Entrepreneurship
Entrepreneurship
Entrepreneurship
EntrepreneurshipFor SMEs, for diversifying markets, internships abroad, international tenders, non-reimbursable subsidies to consolidate exports, subsidies for deployments or specific training in internationalisation.
You’re interested, right?
